Expertise in
6
conditions

Dr. Lynn Howie

Internal Medicine
Henderson County Hospital Corporation
805 6th Ave W Ste 100, 
Hendersonville, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
6
conditions
Henderson County Hospital Corporation
805 6th Ave W Ste 100, 
Hendersonville, NC 

Overview

Lynn Howie is an Internal Medicine provider practicing medicine in Hendersonville, North Carolina.

Dr. Howie is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Pancreatic Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Paget Disease of the Breast.

She is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 54 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in NC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Henderson County Hospital Corporation
805 6th Ave W Ste 100, Hendersonville, NC 28739

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

54 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
View 8 Less Clinical Trials

22 Total Publications

Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: February 22, 2023
Similar Doctors
Expertise in
82
conditions
Dr. Blair Holl
Internal Medicine
Expertise in
82
conditions
Dr. Blair Holl
Internal Medicine

Office

90 Southside Ave Ste 350, 
Asheville, NC 
 (22.8 miles away)
828-277-4810
Languages Spoken:
English
See accepted insurances

Blair Holl is a primary care provider, practicing in Internal Medicine in Asheville, North Carolina. Dr. Holl is highly rated in 82 conditions, according to our data. His clinical expertise encompasses Low Blood Pressure, Familial Chronic Mucocutaneous Candidiasis, Anemia, and Thrush.

Expertise in
24
conditions
Dr. Julia Payne
Internal Medicine
Expertise in
24
conditions
Dr. Julia Payne
Internal Medicine

Palmetto Pulmonary And Critical Care

3 Francis Ste 300, 
Greenville, SC 
 (29.4 miles away)
864-233-8063
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julia Payne is an Internal Medicine provider practicing medicine in Greenville, South Carolina. Dr. Payne is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Acute Interstitial Pneumonia, Endoscopy, and Gastrostomy.

Expertise in
28
conditions
Dr. Gregory Glance
Internal Medicine
Expertise in
28
conditions
Dr. Gregory Glance
Internal Medicine

Asheville Internal Medicine P.A.

60 Livingston St Ste 200, 
Asheville, NC 
 (23.4 miles away)
828-253-4851
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Glance is a primary care provider, practicing in Internal Medicine in Asheville, North Carolina. Dr. Glance is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Cirrhosis, Xanthoma, Familial Combined Hyperlipidemia, and High Cholesterol.

Frequently Asked Questions about Dr. Lynn Howie

How do I make an appointment with Dr. Lynn Howie?

You can book an appointment with Dr. Lynn Howie by calling their office at 828-692-8045. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lynn Howie a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lynn Howie is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lynn Howie specialize in?

While Dr. Lynn Howie is a Internal Medicine, they have specific expertise in Breast Cancer, Pancreatic Cancer, and Upper Tract Urothelial Carcinoma (UTUC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Lynn Howie participate in research or clinical trials?

Yes. Dr. Lynn Howie has published 22 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Lynn Howie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lynn Howie accept my insurance?

Dr. Lynn Howie accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 828-692-8045 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Howie's expertise for a condition
ConditionClose
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile